Her2 Expression and Response of Breast Cancer to Adjuvant Chemotherapy : Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.

www.degruyter.com uses cookies, tags, and tracking settings to store information that help give you the very best browsing experience.
To understand more about cookies, tags, and tracking, see our Privacy Statement
I accept all cookies for the De Gruyter Online site

Jump to ContentJump to Main Navigation

Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.

The Journal of Latvian Academy of Sciences

SCImago Journal Rank (SJR) 2014: 0.213
Source Normalized Impact per Paper (SNIP) 2014: 0.232
Impact per Publication (IPP) 2014: 0.297

Open Access

Her2 Expression and Response of Breast Cancer to Adjuvant Chemotherapy

Alinta Hegmane1 / Uldis Vikmanis1

Latvian Oncology Centre, Rīga Eastern University Hospital, Hipokrāta iela 4, Rīga, LV-1079, LATVIA1

Faculty of Medicine, University of Latvia, Šarlotes iela 1a, Rīga, LATVIA2

This content is open access.

Citation Information: Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.. Volume 62, Issue 3, Pages 129–132, ISSN (Print) 1407-009X, DOI: 10.2478/v10046-008-0023-0, November 2008

Publication History

Published Online:

Her2 Expression and Response of Breast Cancer to Adjuvant Chemotherapy

Expression of the human epidermal growth factor receptor type 2 (HER2) in breast cancer patients may predict response to anthracycline or non anthracycline-based adjuvant chemotherapy. A total of 192 breast cancer patients diagnosed at the Latvian Oncology Centre from January 2002 to August 2005 were included in the study. Patients had histopathologically confirmed breast cancer, had undergone radical surgery and received at least four courses of adjuvant chemotherapy. HER2 expression was evaluated by immunohystochemical analysis. Median follow-up time was 32.1 months. In HER2 negative patients, the mean time to recurrence was 26.9 months (SD 1.465; 95%CI 23.9-29.4) for patients received antracycline-based chemotherapy and 33.2 months (SD 1.308; 95%CI 30.6-35.8) in the CMF chemotherapy group (P < 0.05). These HER2 negative patients could be treated with a less toxic regimen of CMF. In HER2 overexpressed patients receiving anthracycline based chemotherapy, mean time to recurrence was 30 months (SD 2.170; 95%CI 25.7-34.4) compared with 29.2 months (SD 1.965; 95%CI 25.4-33.1) in patients who received CMF, but the difference was not significant (P > 0.05).

Her2 Ekspresijas Loma Krūts Vēža Adjuvantās Ķīmijterapijas Izvēlē

Cilvēka epidermālā augšanas faktora receptora 2 (HER2) ekspresijai var būt nozīme, lai izvēlētos adjuvantu ķīmijterapiju ar vai bez antraciklīniem pacientēm ar krūts vēzi. Pētījumā tika iekļautas 192 pacientes, kurām Latvijas Onkologijas centrā laika posmā no 2002. gada janvāra līdz 2005. gada augustam tika diagnosticēts krūts vēzis. Galvenie iekļaušanas kritēriji bija morfologiski verificēta krūts vēža diagnoze un imūnhistoķīmiski noteikts HER2. Pacientēm bija izdarīta radikāla operācija un vismaz četri adjuvantas ķīmijterapijas kursi. Vidējais novērošanas laiks bija 32,1 mēnesis. Pacientēm, kurām nebija novērota HER2 receptora pārmērīga ekspresija un kuras sañēma ķīmijterapiju ar antraciklīniem, vidējais laiks līdz recidīvam bija 26,9 mēneši (SD 1.465; 95%CI 23,9-29,4), CMF grupā 33,2 mēneši (SD 1,308; 95%CI 30,6-35,8), atšķirība ir būtiska (P < 0,05), šīm pacientēm var rekomendēt mazāk toksisku CMF ķīmijterapiju. Pacientēm ar HER2 receptora pārmērīgu ekspresiju, kuras sañēma ķīmijterapiju ar antraciklīniem, vidējais laiks līdz recidīvam bija 30 mēneši (SD 2.170; 95%CI 25,7-34,4) salīdzinājumā ar 29,2 mēnešiem (SD 1.965; 95%CI 25,4-33,1) CMF ķīmijterapijas grupā, atšķirība nav būtiska (P > 0,05).

Keywords: breast cancer; HER2; adjuvant chemotherapy

  • Anonymous (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on reccurrence and 15-year survival: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Lancet, 365 (9472), 1687-1717.

  • De Laurentiis, M., Caputo, F., Massarelli, E., Forestieri, V., Vernaglia, A., Carlomagno, C., Lauria, R., Bianco, A. R., De Placido, S. (2001). HER2 expression and anthracycline effect: Results from the Naple GUN 3 randomized trial. Proc. Am. Soc. Clin. Oncol., 20, 34A (abstract 133).

  • Dressler, L. G., Berry, D. A., Broadwater, G., Cowan, D., Cox, K., Griffin, S., Miller, A., Tse, J., Novotny, D., Persons, D. L., Barcos, M., Henderson, I. C., Liu, E. T., Thor, A., Budman, D., Muss, H., Norton, L., Hayes, D. F. (2005). Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J. Clin. Oncol., 23(19), 4287-4297.

  • Gusterson, B. A., Gelber, R. D., Goldhirsch, A., Price, K. N., Save-Soderborgh, J., Anbazhagan, R., Styles, J., Rudenstam, C. M., Golouh, R., Reed, R. (1992). Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J. Clin. Oncol., 10(7), 1049-1056.

  • Harris, L. N., Yang, L., Liotcheva, V., Pauli, S., Iglehart, J. D., Colvin, O. M., Hsieh, T. S. (2001). Induction of topoisomerase II activity after Erb B2 activation is associated with a differential response to breast cancer chemotherapy. Clin. Cancer Res., 7(6), 1497-1504.

  • Jarvinen, T. A., Liu, E. T. (2003). HER-2/neu and topoisomerase IIalpha in breast cancer. Breast Cancer Res. Treat., 78(3), 299-311. [CrossRef]

  • Jarvinen, T. A. H., Tanner, M., Rantonen, V., Barlund, M., Borg, A., Grénman, S., Isola, J. (2000). Amplification and deletion of topoisomerase II associate with Erb B-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Amer. J. Pathol., 156(3), 839-847.

  • Knoop, A. S., Knudsen, H., Balslev, E., Rasmussen, B. B., Overgaard, J., Nielsen, K. V., Schonau, A., Gunnarsdottir, K., Olsen, K. E., Mouridsen, H., Ejlertsen, B. (2005). Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil. J. Clin. Oncol., 23(30), 7483-7490.

  • Konecny, G., Fritz, M., Untch, M., Lebeau, A., Felber, M., Lude, S., Beryt, M., Hepp, H., Slamon, D., Pegram, M. (2001). HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer. Breast Cancer Res. Treat., 69(1), 53-63.

  • Levine, M. N., Bramwell, H., Pritchard, K. I., Shepherd, L. E., Tu, D., Paul, N. (1998). Randomised trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J. Clin. Oncol., 16(22), 2651-2658.

  • Paik, S., Bryant, J., Park, C., Fisher, B., Tan-Chiu, E., Hyams, D., Fisher, E. R., Lippman, M. E., Wickerham, D. L., Wolmark, N. (1998). erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J. Natl. Cancer Inst., 90(18), 1361-1370.

  • Pegram, M. D., Finn, R. S., Arzoo, K., Beryt, M., Pietras, R. J., Slamon, D. J. (1997). The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene, 15(5), 537-547. [PubMed] [CrossRef]

  • Pinder, M. C., Duan, Z., Goodwin, J. S., Hortobagyi, G. N., Giordano, S. H. (2007). Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J. Clin. Oncol., 25(25), 3808-3815. [CrossRef] [PubMed]

  • Pritchard, K. I., Shepherd, L. E., O'Malley, F. P., Andrulis, I. L., Tu, D., Bramwell, V. H., Levine, M. N. (2006). HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N. Engl. J. Med., 354(20), 2103-2111.

  • Slamon, D. J., Godolphin, W., Jones, J. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., Press, M. F. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244(4905), 707-712.

  • Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Lager, A., McShane, L. M., Paik, S., Pegram, M. D., Perez, E. A., Press, M. F., Rhodes, A., Sturgeon, C., Taube, S. E., Tubbs, R., Vance, G. H., van de Vijver, M., Wheeler, T. M., Hayes, D. F. (2007). American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. J. Clin. Oncol., 25(1), 118-145. [Web of Science]

Comments (0)

Please log in or register to comment.